FREMONT, Calif. — January 8, 2026 — Leads & Copy — Personalis, Inc. (Nasdaq: PSNL) has released its preliminary, unaudited financial and operational results for the fourth quarter and full year ending December 31, 2025.
The company anticipates total revenue in the range of $69.0 to $70.0 million for the year, compared to $84.6 million in 2024. Clinical test revenue saw significant growth, reaching approximately $2.0 million, more than double the $0.8 million reported the previous year. Clinical test volume also surged, reaching approximately 16,233 tests, a nearly 400% increase from the 3,285 tests in 2024. This exceeded the company’s internal growth targets by over 20%.
For the fourth quarter, Personalis expects revenue to be between $17.0 million and $18.0 million. The company delivered 6,183 clinical tests, a 41% sequential increase over the third quarter of 2025. Preliminary clinical test revenue for the quarter is approximately $0.9 million, compared to $0.2 million in the same period of the prior year.
Pharma tests, services, and other customers contributed approximately $49.0 million to $50.0 million to the full year revenue, and $11.6 million to $12.6 million for the fourth quarter. Revenue from enterprise sales (Natera) and population sequencing (the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP)) totaled approximately $18.0 million for the year and $4.5 million for the quarter.
Personalis ended the year with approximately $240.0 million in cash, cash equivalents, and short-term investments, including $109.0 million in net proceeds from its At-The-Market (ATM) sales program.
According to Chris Hall, Chief Executive Officer and President, the company’s Win-in-MRD strategy is proving effective. Hall noted the significant clinical volume growth and the increasing demand from oncologists for the company’s NeXT Personal platform.
A key development was securing Medicare coverage for breast cancer surveillance in the fourth quarter, which is expected to boost clinical revenue and market share growth in the MRD space.
The company also highlighted the publication of TRACERx data in the journal Cell, demonstrating the clinical importance of Personalis’ ultrasensitive MRD approach, and VHIO data in Clinical Cancer Research, reinforcing the clinical validity of the NeXT Personal platform.
These preliminary financial results are subject to the company’s standard year-end accounting procedures and external audit.
Personalis aims to transform cancer management through personalized testing, with products designed to detect minimal residual disease (MRD) and recurrence, enable targeted therapy selection, and enhance biomarker strategy for drug development.
Chris Hall, Chief Executive Officer and President.
Source: Personalis, Inc.
